Trial Profile

A Phase I/II Study of Vorinostat (Zolinza) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vorinostat (Primary) ; Capecitabine; Cisplatin
Indications Gastric cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

12 May 2016 Status changed from active, no longer recruiting to completed, as per results published in the British Journal of Cancer.
12 May 2016 Primary endpoint has not been met. (Phase II - 6-month progression-free survival (PFS) rate), as per results published in the British Journal of Cancer.
12 May 2016 Results of phase II portion and biomarker analysis published in the British Journal of Cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com